The DOI matches its Crossref record; 234 of the 236 references it cites were found in a registry or an index.
p21 in cancer: intricate networks and multiple activities
Open accessAbstract
One of the main engines that drives cellular transformation is the loss of proper control of the mammalian cell cycle. The cyclin-dependent kinase inhibitor p21 (also known as p21WAF1/Cip1) promotes cell cycle arrest in response to many stimuli. It is well positioned to function as both a sensor and an effector of multiple anti-proliferative signals. This Review focuses on recent advances in our understanding of the regulation of p21 and its biological functions with emphasis on its p53-independent tumour suppressor activities and paradoxical tumour-promoting activities, and their implications in cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“p21 is a potent cell-cycle inhibitor (39)”
From Txnip Enhances Fitness of Dnmt3a -Mutant Hematopoietic Stem Cells via p21 (2022) · cites this paper as [39]
In the citing paper
“CDKN1A (p21, WAF1, CIP1) was among the first p53 target genes11, 12 to be identified and is now recognized as an encoder for a major cell cycle checkpoint control protein.145”
From Census and evaluation of p53 target genes (2017) · cites this paper as [145]
In the citing paper
“As p21 is rarely genetically affected in cancers [1,124]”
From CDK-Independent and PCNA-Dependent Functions of p21 in DNA Replication (2020) · cites this paper as [1]
In the citing paper
“Members of the Krüppel-like factor (KLF) transcription factor (TF) family can activate the CDKN1A gene by cooperating with p300-CREBBP (Aliouat-Denis et al., 2005; Abbas and Dutta, 2009).”
From Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype (2021) · cites this paper as Abbas and Dutta, 2009
In the citing paper
“p21WAF1/CIP1 can also be activated by p53 independent mechanisms by other stimulators such as nuclear receptors including androgen, vitamin D and retinoid receptors.”
From Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype (2021) · cites this paper as Abbas and Dutta, 2009
In the citing paper
“Although this is the first detectable event, it is more likely that main role of p21 lies in its capacity to trigger pRb-mediated repression of cell cycle regulators (Fig. 2, for more information on p21 functions (see ref. 98 ).”
From Senescence from G2 arrest, revisited (2015) · cites this paper as [98]
In the citing paper
“For example, cyclin-dependent kinase inhibitor 1A (CDKN1A), a tumor suppressor that is downregulated in multiple cancers (106), is targeted by at least 28 miRNAs and many of which are upregulated together in cancers where CDKN1A has been implicated (107).”
From Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation (2018) · cites this paper as [106]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Cell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957 · cited 1×
“CDK1, at least in some tissues, may be the crucial target of p21 in tumorigenesi”
BackgroundRequirement for p53 and p21 to Sustain G 2 Arrest After DNA Damage
Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.282.5393.1497 · Cited by 2,803
Mice Lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control
Deng, C., Zhang, P., Wade Harper, J., Elledge, S. J., & Leder, P. (1995) · Cell · doi:10.1016/0092-8674(95)90039-x · Cited by 2,113
Tumor spectrum analysis in p53-mutant mice
Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., & Weinberg, R. A. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00002-6 · Cited by 2,051
Xu, X., Yuan, G., Li, Q., Shan, S.-L., & Jiang, S. (2012) · Hepatogastroenterology · doi:10.5754/hge12404 · Cited by 1,825
Restoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820 · cited 1×
“Recent work suggests that tumour regression can be achieved through the reactivation of senescence, for example by restoring p53 functio”
BackgroundPCNA, the Maestro of the Replication Fork
Moldovan, G.-L., Pfander, B., & Jentsch, S. (2007) · Cell · doi:10.1016/j.cell.2007.05.003 · Cited by 1,796
Cellular senescence in cancer and aging.
Collado, M., Blasco, M. A., & Serrano, M. (2007) · Cell · doi:10.1016/j.cell.2007.07.003 · Cited by 1,708
Research works printed but not linked: 1
- Martin-Caballero, J., Flores, J. M., Garcia-Palencia, P. & Serrano, M. Tumor susceptibility of p21Waf1/Cip1-deficient mice. Cancer Res. 61, 6234–6238 (2001). This study demonstrates that deletion of Cdkn1a in mice results in spontaneous tumours but with late onset.
Cited by
Sorted by citations
Items 801–900 of 1,005
Frequent β-catenin gene mutations in atypical polypoid adenomyoma of the uterus
Takahashi, H., Yoshida, T., Matsumoto, T., Kameda, Y., Takano, Y., Tazo, Y., Inoue, H., & Saegusa, M. (2013) · Human Pathology · doi:10.1016/j.humpath.2013.06.020 · Cited by 36
Hsieh, H., Shen, C., Lin, R.-I., Feng, Y.-M., Huang, S., Wang, Y., Wu, S., Hsu, C., & Chan, M. W. Y. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.09.018 · Cited by 36
A Systems’ Biology Approach to Study MicroRNA-Mediated Gene Regulatory Networks
Lai, X., Bhattacharya, A., Schmitz, U., Kunz, M., Vera, J., & Olaf Wolkenhauer, A. (2013) · BioMed Research International · doi:10.1155/2013/703849 · Cited by 36
Luna‐Vital, D. A., de Mejı́a, E. G., & Loarca-Piña, G. F. (2016) · Journal of Functional Foods · doi:10.1016/j.jff.2016.02.021 · Cited by 36
Romanov, V. S., & Rudolph, K. L. (2016) · Nature Cell Biology · doi:10.1038/ncb3382 · Cited by 41
KLF6 depletion promotes NF-κB signaling in glioblastoma
Masilamani, A. P., Ferrarese, R., Kling, E., Thudi, N. K., Kim, H., Scholtens, D. M., Dai, F., Hadler, M., Unterkircher, T., Platania, L., et al. (2017) · Oncogene · doi:10.1038/onc.2016.507 · Cited by 36
Moussa, R., Park, K. C., Kovačević, Ž., & Richardson, D. R. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.03.027 · Cited by 39
GMDS knockdown impairs cell proliferation and survival in human lung adenocarcinoma
Wei, X., Zhang, K., Qin, H., Zhu, J., Qin, Q., Yang, Y. P., & Wang, H. (2018) · BMC Cancer · doi:10.1186/s12885-018-4524-1 · Cited by 36
Increased EZH2 expression during the adenoma‑carcinoma sequence in colorectal cancer
Ohuchi, M., Sakamoto, Y., Tokunaga, R., Kiyozumi, Y., Nakamura, K., Izumi, D., Kosumi, K., Harada, K., Kurashige, J., Iwatsuki, M., et al. (2018) · Oncology Letters · doi:10.3892/ol.2018.9240 · Cited by 37
Schmidtova, S., Kaľavská, K., & Kučerová, L. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0730-x · Cited by 36
Multiple functions of p21 in cancer radiotherapy
Kuang, Y., Kang, J. L., Li, H., Liu, B., Zhao, X., Li, L., Jin, X., & Li, Q. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03529-2 · Cited by 37
Cytoplasmic Localization of p21 Protects Trophoblast Giant Cells from DNA Damage Induced Apoptosis
de Renty, C., Depamphilis, M., & Ullah, Z. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097434 · Cited by 36
Liu, J., Tang, X., Li, C., Pan, C., Li, Q., Geng, F., & Pan, Y. (2015) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2015.05.004 · Cited by 36
Tinkum, K. L., Marpegán, L., White, L. S., Sun, J., Herzog, E. D., Piwnica-Worms, D. R., & Piwnica-Worms, H. M. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.05243-11 · Cited by 36
Regulation of replication fork speed: Mechanisms and impact on genomic stability
Merchut‐Maya, J. M., Bártek, J., & Maya‐Mendoza, A. (2019) · DNA repair · doi:10.1016/j.dnarep.2019.102654 · Cited by 36
Cellular senescence in liver diseases: From mechanisms to therapies
Ge, T., Shao, Y., Bao, X., Xu, W., & Lu, C. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110522 · Cited by 37
Deubiquitinase-Targeting Chimeras (DUBTACs) as a Potential Paradigm-Shifting Drug Discovery Approach
Ma, Z., Zhou, M., Chen, H., Shen, Q., & Zhou, J. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02975 · Cited by 43
Cell cycle inhibitor p21/ WAF1/ CIP1 as a cofactor of MITF expression in melanoma cells
Šestáková, B., Ondrušová, Ľ., & Vachtenheim, J. (2010) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2010.00670.x · Cited by 37
Wang, Y., Gu, X., Zhang, G., Wang, L., Wang, T., Zhao, Y., Zhang, X., Zhou, Y., Kadin, M. E., & Tu, P. (2014) · Blood · doi:10.1182/blood-2013-10-534693 · Cited by 35
p21 Cooperates with DDB2 Protein in Suppression of Ultraviolet Ray-induced Skin Malignancies
Stoyanova, T. I., Roy, N., Bhattacharjee, S., Kopanja, D., Valli, T., Bagchi, S., & Raychaudhuri, P. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.295816 · Cited by 37
Nucleolar Disruption Ensures Nuclear Accumulation of p21 upon DNA Damage
Abella, N., Brun, S., Calvo, M., Tapia, O., Weber, J. D., Berciano, M. T., Lafarga, M., Bachs, O., & Agell, N. (2010) · Traffic · doi:10.1111/j.1600-0854.2010.01063.x · Cited by 39
Mathuram, T. L., Ravikumar, V., Reece, L. M., Selvaraju, K., Sasikumar, C. S., & Cherian, K. M. (2016) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2016.07.013 · Cited by 33
Specific Triacylglycerols AccumulateviaIncreased Lipogenesis During 5-FU-Induced Apoptosis
Li, N., Lizardo, D. Y., & Atilla‐Gokcumen, G. E. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00410 · Cited by 35
Lin, G., Zhu, S., Wu, Y., Song, C., Wang, W., Zhang, Y., Chen, Y.-L., & He, Z. (2017) · Scientific Reports · doi:10.1038/s41598-017-03231-9 · Cited by 35
RetractedNovel prognostic marker PRMT1 regulates cell growth via downregulation of CDKN1A in HCC
Ryu, J., Kim, S., Son, M., Jeon, S.-J., Oh, J., Lim, J. H., Cho, S., Jung, C., Hamamoto, R., Kim, D., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23296 · Cited by 35
Alves, M. R., Melo, N. C. E., Barros‐Filho, M. C., do Amaral, N. S., Ilelis, F., Baiocchi, G., Soares, F. A., Brot, L. D., & Rocha, R. M. (2018) · Cancer Medicine · doi:10.1002/cam4.1530 · Cited by 34
Maijaroen, S., Jangpromma, N., Daduang, J., & Klaynongsruang, S. (2018) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2018.07.007 · Cited by 38
Vacante, F., Senesi, P., Montesano, A., Paini, S., Luzi, L., & Terruzzi, I. (2019) · International Journal of Endocrinology · doi:10.1155/2019/7570146 · Cited by 35
Fetal origin confers radioresistance on liver macrophages via p21
Soysa, R., Lampert, S., Yuen, S. Y., Douglass, A. N., Li, W., Pfeffer, K., & Crispe, I. N. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.04.015 · Cited by 37
Targeting PCNA with Peptide Mimetics for Therapeutic Purposes
Horsfall, A. J., Abell, A. D., & Bruning, J. B. (2019) · ChemBioChem · doi:10.1002/cbic.201900275 · Cited by 35
Huang, C., Wu, S., Li, W., Herkilini, A., Miyagishi, M., Zhao, H., & Kasim, V. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.08.070 · Cited by 34
Zhao, H., Sun, J. M., Shao, J.-S., Zou, Z., Qiu, X., Wang, E., & Wu, G. (2019) · Journal of Cancer · doi:10.7150/jca.30772 · Cited by 39
LRIG1 is a pleiotropic androgen receptor-regulated feedback tumor suppressor in prostate cancer
Li, Q., Liu, B., Chao, H., Ji, Y., Lu, Y., Mehmood, R., Jeter, C. R., Chen, T., Moore, J. R., Li, W., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13532-4 · Cited by 34
From Development to Aging: The Path to Cellular Senescence
Sacco, A., Belloni, L., & Latella, L. (2020) · Antioxidants and Redox Signaling · doi:10.1089/ars.2020.8071 · Cited by 38
Rai, R., Essel, K. G., Benbrook, D. M., Garland, J., Zhao, Y. D., & Chandra, V. (2020) · Cancers · doi:10.3390/cancers12051273 · Cited by 35
Pelletier, J., Riaño‐Canalias, F., Almacellas, E., Mauvezin, C., Samino, S., Feu, S., Menoyo, S., Domostegui, A., Garcia‐Cajide, M., Salazar, R., et al. (2020) · The EMBO Journal · doi:10.15252/embj.2019103838 · Cited by 36
Schmidt, A.-K., Pudelko, K., Boekenkamp, J.-E., Berger, K., Kschischo, M., & Bastians, H. (2020) · Oncogene · doi:10.1038/s41388-020-01524-4 · Cited by 35
Nguyen, T., Guo, R., Chai, J., Wu, J., Liu, J., Chen, X., Abdel-Rahman, M. A., Xia, H., & Xu, X. (2022) · Toxins · doi:10.3390/toxins14100717 · Cited by 35
Rego, M. A., Harney, J. A., Mauro, M., Shen, M., & Howlett, N. G. (2011) · Oncogene · doi:10.1038/onc.2011.237 · Cited by 37
UVB-Induced p21 degradation promotes apoptosis of human keratinocytes
Lei, X., Liu, B., Han, W., Ming, M., & He, Y. (2010) · Photochemical & Photobiological Sciences · doi:10.1039/c0pp00244e · Cited by 34
Forni, C., Braglia, R., Mulinacci, N., Urbani, A., Ronci, M., Gismondi, A., Tabolacci, C., Provenzano, B., Lentini, A., & Beninati, S. (2013) · Molecular BioSystems · doi:10.1039/c3mb70316a · Cited by 35
Lee, Y.-S., Chin, Y., Yang, Y. S. H., Wei, P., Wu, H., Shih, A., Lu, Y.-T., Pedersen, J. Z., Incerpi, S., Liu, L. F., et al. (2016) · Steroids · doi:10.1016/j.steroids.2016.03.006 · Cited by 35
Jagged-2 (JAG2) enhances tumorigenicity and chemoresistance of colorectal cancer cells
Vaish, V., Kim, J., & Shim, M. (2017) · Oncotarget · doi:10.18632/oncotarget.18391 · Cited by 35
Shin, H. J., Kim, D. N., & Lee, S. K. (2011) · Molecules and Cells · doi:10.1007/s10059-011-0066-y · Cited by 35
Maheshwari, M., Yadav, N., Hasanain, M., Pandey, P. K., Sahai, R., Choyal, K., Singh, A., Nengroo, M. A., Saini, K. K., Kumar, D., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05486-1 · Cited by 35
Effects of p21-activated kinase 1 inhibition on 11q13-amplified ovarian cancer cells
Prudnikova, T. Y., Cruz, O. V., Rawat, S. J., Cai, K. Q., & Chernoff, J. (2015) · Oncogene · doi:10.1038/onc.2015.278 · Cited by 34
Sun, H. R., Olsen, T., Zhu, J., Tao, J., Ponnaiya, B., Amundson, S. A., Brenner, D. J., & Lin, Q. (2014) · RSC Advances · doi:10.1039/c4ra13356k · Cited by 34
Janečková, L., Pospíchalová, V., Fafílek, B., Vojtěchová, M., Turečková, J., Dobeš, J., Dubuissez, M., Leprince, D., Dibus, N., Horázná, M., et al. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0033 · Cited by 34
YAN, K.-H., Lin, Y., Hsiao, C., Wen, Y., Lin, K.-H., LIU, C.-C., Hsieh, M., Yao, C., Yan, M., Lai, G., et al. (2013) · Oncology Letters · doi:10.3892/ol.2013.1259 · Cited by 34
Winter, J. N., Li, S., Aurora, V., Variakojis, D., Nelson, B. P., Krajewska, M., Zhang, L., Habermann, T. M., Fisher, R. I., Macon, W. R., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1219 · Cited by 34
Oncogenic Herpesvirus Utilizes Stress-Induced Cell Cycle Checkpoints for Efficient Lytic Replication
Balistreri, G., Viiliäinen, J., Turunen, M. M., Díaz, R., Lyly, L., Pekkonen, P., Rantala, J., Ojala, K., Sarek, G., Teesalu, M., et al. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005424 · Cited by 34
Cheng, S., Zhang, X., Huang, N., Qiu, Q., Jin, Y. H., & Jiang, D. (2016) · BMC Cancer · doi:10.1186/s12885-016-2294-1 · Cited by 34
Birner, P., Schoppmann, A., Schindl, M., Dinhof, C., Jesch, B., Berghoff, A. S., & SCHOPPMANN, S. F. (2012) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2011-200463 · Cited by 34
JNKs function as CDK4-activating kinases by phosphorylating CDK4 and p21
Colleoni, B., Paternot, S., Pita, J. M. G., Bisteau, X., Coulonval, K., Davis, R. J., Raspé, E., & Roger, P. P. (2017) · Oncogene · doi:10.1038/onc.2017.7 · Cited by 33
Reyes‐Gibby, C. C., Melkonian, S. C., Wang, J., Yu, R. K., Shelburne, S. A., Lu, C. S., Gunn, G. B., Chambers, M. S., Hanna, E. Y., Yeung, S. J., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0180396 · Cited by 34
Nölting, S., Rentsch, J., Freitag, H., Detjen, K. M., Briest, F., Möbs, M., Weissmann, V., Siegmund, B., Auernhammer, C. J., Prada, E. T. A., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182852 · Cited by 34
Chen, J., Zhang, Y., Li, G., Peng, F., Jie, X.-M., She, J., Dongye, G.-Z., Zou, Z., Rong, S.-W., & Chen, L. (2017) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-017-1528-2 · Cited by 33
Iketani, M., Sekimoto, K., Igarashi, T., Takahashi, M. M., Komatsu, M., Sakane, I., Takahashi, H., Kawaguchi, H., Ohtani‐Kaneko, R., & Ohsawa, I. (2018) · Scientific Reports · doi:10.1038/s41598-018-35239-0 · Cited by 35
Zhang, Y., Zhang, Q., Xin, W., Liu, N., & Zhang, H. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s180610 · Cited by 34
Molecular mechanisms and systemic targeting of NRF2 dysregulation in cancer
Kang, J.-S., Nam, L. B., Yoo, O.-K., & Keum, Y. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114002 · Cited by 35
A tissue-bioengineering strategy for modeling rare human kidney diseases in vivo
Hernandez, J. O. R., Wang, X., Segoviano, M. V., López-Marfil, M., Sobral-Reyes, M. F., Moran-Horowich, A., Sundberg, M., Lopez-Cantu, D. O., Probst, C. K., Ruiz‐Esparza, G. U., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26596-y · Cited by 36
Haarer, E. L., Theodore, C. J., Guo, S., Frier, R. B., & Campellone, K. G. (2023) · PLoS Genetics · doi:10.1371/journal.pgen.1010045 · Cited by 33
Perez‐Neut, M., Rao, V. R., & Gentile, S. (2015) · Oncotarget · doi:10.18632/oncotarget.3797 · Cited by 34
Tinkum, K. L., White, L. S., Marpegán, L., Herzog, E. D., Piwnica-Worms, D. R., & Piwnica-Worms, H. M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.494328 · Cited by 34
Antitumor activity of glycyrol via induction of cell cycle arrest, apoptosis and defective autophagy
Xu, M., & Kim, Y. S. (2014) · Food and Chemical Toxicology · doi:10.1016/j.fct.2014.10.023 · Cited by 34
Defective endomitosis during megakaryopoiesis leads to thrombocytopenia in Fanca−/− mice
Pawlikowska, P., Fouchet, P., Vainchenker, W., Rosselli, F., & Naim, V. (2014) · Blood · doi:10.1182/blood-2014-01-551457 · Cited by 34
Chen, I.-P., Henning, S. W., Faust, A., Boukamp, P., Volkmer, B., & Greinert, R. (2011) · Photochemical & Photobiological Sciences · doi:10.1039/c1pp05197k · Cited by 37
Upregulated LINC00565 Accelerates Ovarian Cancer Progression By Targeting GAS6
Gong, M., Luo, C., Meng, H., Li, S., Nie, S., Jiang, Y., Wan, Y., Li, H., & Cheng, W. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s227758 · Cited by 33
Huisman, C., van der Wijst, M. G. P., Falahi, F., Overkamp, J., Karsten, G., Terpstra, M. M., Kok, K., van der Zee, A. G., Schuuring, E. M. D., Wisman, G. B. A., et al. (2015) · Epigenetics · doi:10.1080/15592294.2015.1034415 · Cited by 33
Expression of TP53 Isoforms p53β or p53γ Enhances Chemosensitivity in TP53null Cell Lines
Silden, E., Hjelle, S. M., Wergeland, L., Sulen, A., Andresen, V., Bourdon, J., Micklem, D., McCormack, E., & Gjertsen, B. T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056276 · Cited by 33
Correlation of STAT1 with Apoptosis and Cell-Cycle Markers in Esophageal Squamous Cell Carcinoma
Zhang, Y., Zhang, Y., Yun, H., Lai, R. L., & Su, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113928 · Cited by 33
Cdk5 Directly Targets Nuclear p21CIP1 and Promotes Cancer Cell Growth
Huang, P.-H., Chen, M., Peng, Y.-T., Kao, W.-H., Chang, C., WANG, Y.-C., Lai, C., Hsieh, J., Wang, J.-H., Lee, Y.-T., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3253 · Cited by 33
Zhang, S., Xia, C., Xu, C., Liu, J. L., Zhu, H. J., Yang, Y., Xu, F., Zhao, J.-F., Chang, Y., & Zhao, Q. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.3855 · Cited by 33
Rasool, F., Nayak, D., Katoch, A., Faheem, M. M., Yousuf, S. K., Hussain, N., Belawal, C., Satti, N. K., Goswami, A., & Mukherjee, D. (2017) · Scientific Reports · doi:10.1038/s41598-017-13664-x · Cited by 33
Liu, J., Abdelmagid, S. A., Pinelli, C. J., Monk, J. M., Liddle, D. M., Hillyer, L. M., Hucik, B., Silva, A., Subedi, S. D., Wood, G. A., et al. (2017) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2017.12.011 · Cited by 33
Ibnat, N., Kamaruzman, N. I., Ashaie, M., & Chowdhury, E. H. (2019) · Gene · doi:10.1016/j.gene.2019.02.082 · Cited by 33
Function of p21 (Cip1/Waf1/CDKN1A) in Migration and Invasion of Cancer and Trophoblastic Cells
Kreis, N., Friemel, A., Ritter, A., Roth, S., Rolle, U., Louwen, F., & Yuan, J. (2019) · Cancers · doi:10.3390/cancers11070989 · Cited by 33
Fenerich, B. A., Fernandes, J. C., Alves, A. P. N. R., Coelho‐Silva, J. L., Scopim‐Ribeiro, R., Scheucher, P. S., Eide, C. A., Tognon, C. E., Druker, B. J., Rego, E. M., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0102-5 · Cited by 34
Molecular connections between circadian rhythm and genome maintenance pathways
Kolinjivadi, A. M., Chong, S. T., & Ngeow, J. Y. Y. (2020) · Endocrine Related Cancer · doi:10.1530/erc-20-0372 · Cited by 32
Aharon-Hefetz, N., Frumkin, I., Mayshar, Y., Dahan, O., Pilpel, Y., & Rak, R. (2020) · eLife · doi:10.7554/elife.58461 · Cited by 37
Suwannakot, K., Sritawan, N., Prajit, R., Aranarochana, A., Sirichoat, A., Pannangrong, W., Wigmore, P. M., & Welbat, J. U. (2021) · Antioxidants · doi:10.3390/antiox10040615 · Cited by 33
The Intricate Interplay between Cell Cycle Regulators and Autophagy in Cancer
Ziegler, D. V., Huber, K., & Fajas, L. (2021) · Cancers · doi:10.3390/cancers14010153 · Cited by 34
Ghanem, A., Al-Karmalawy, A. A., Maksoud, A. I. A. E., Hanafy, S. M., Emara, H. A., Saleh, R. M., & Elshal, M. F. (2022) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2022.100869 · Cited by 34
Tsuchiya, K., Yoshimura, K., Iwashita, Y., Inoue, Y., Ohta, T., Watanabe, H., Yamada, H., Kawase, A., Tanahashi, M., Ogawa, H., et al. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-022-00451-8 · Cited by 36
Gao, Y., Chen, B., Wang, R., Xu, A., Wu, L., Lü, H., & Zhao, G. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01140-z · Cited by 34
Ibrahim, A. A., Gaber, S. A. A., Kabil, M. F., Ahmed-Farid, O. A.-H., Hirsch, A. K. H., El-sherbiny, I. M., & Nasr, M. (2022) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2022.2139370 · Cited by 33
Proliferating Cell Nuclear Antigen (PCNA) Interactions in Solution Studied by NMR
Biasio, A. D., Campos‐Olivas, R., Sánchez, R., López-Alonso, J. P., Pantoja‐Uceda, D., Merino, N., Villate, M., Martin-Garcia, J. M., Castillo, F., Luque, I., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048390 · Cited by 33
Humbert, L., Ghozlan, M., Canaff, L., Tian, J., & Lebrun, J. J. (2015) · BMC Cancer · doi:10.1186/s12885-015-1177-1 · Cited by 37
Lee, M., Zhang, S., Lin, S. H. S., Wang, X., Darżynkiewicz, Z., Zhang, Z., & Lee, E. (2013) · Cell Cycle · doi:10.4161/cc.27407 · Cited by 35
Suppression of colon carcinogenesis by targeting Notch signaling
Miyamoto, S., Nakanishi, M., & Rosenberg, D. W. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt191 · Cited by 33
Complex regulation of LCoR signaling in breast cancer cells
Jalaguier, S., Teyssier, C., Achour, T. N., Lucas, A., Bonnet, S., Rodriguez, C., Elarouci, N., Lapierre, M., & Cavaillès, V. (2017) · Oncogene · doi:10.1038/onc.2017.97 · Cited by 33
Akbari, S., Darban, R. A., Javid, H., Esparham, A., & Hashemy, S. I. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02551-0 · Cited by 32
Zheng, C., Wei, Y., Zhang, P., Lin, K., He, D., Teng, H., Manyam, G. C., Zhang, Z., Liu, W., Lee, H. R. L., et al. (2023) · Nature Structural & Molecular Biology · doi:10.1038/s41594-023-01117-1 · Cited by 36
Sun, J., Gui, Y., Zhou, S., & Zheng, X. (2023) · Journal of Advanced Research · doi:10.1016/j.jare.2023.11.006 · Cited by 38
Loss of p21Cip1/CDKN1A renders cancer cells susceptible to Polo-like kinase 1 inhibition
Kreis, N., Louwen, F., Zimmer, B., & Yuan, J. (2014) · Oncotarget · doi:10.18632/oncotarget.2844 · Cited by 33
MAPK Kinase 3 Is a Tumor Suppressor with Reduced Copy Number in Breast Cancer
MacNeil, A. J., Jiao, S., McEachern, L. A., Yang, Y. J., Dennis, A., Yu, H., Xu, Z., Marshall, J. S., & Lin, T. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1310 · Cited by 32
Katsume, A., Okigaki, M., Matsui, A., Che, J., Adachi, Y., Kishita, E., Yamaguchi, S., Ikeda, K., Ueyama, T., Matoba, S., et al. (2011) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.110.221804 · Cited by 33
RetractedAssociation of p21 SNPs and risk of cervical cancer among Chinese women
Wang, N., Wang, S., Zhang, Q., Lü, Y., Wei, H., Li, W., Zhang, S., Yin, D., & Ou, Y. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-589 · Cited by 32
Loss of CDKN2B Promotes Fibrosis via Increased Fibroblast Differentiation Rather Than Proliferation
Scruggs, A. M., Koh, H. B., Tripathi, P., Leeper, N. J., White, E. S., & Huang, S. K. (2018) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2017-0298oc · Cited by 33
TRAF6 regulates EGF-induced cell transformation and cSCC malignant phenotype through CD147/EGFR
Zhang, X., Wu, L., Xiao, T., Tang, L. Y., Jia, X., Guo, Y., Zhang, J., Li, J., He, Y., Su, J., et al. (2018) · Oncogenesis · doi:10.1038/s41389-018-0030-1 · Cited by 32
Metadata
- Authors
- Abbas, T., & Dutta, A.
- Affiliations
- University of Virginia (US)
- Corresponding author
- Abbas, Tarek
- Dutta, Anindya
- Venue
- Nature Reviews Cancer
- Published
- 2009-05-14
- Volume
- 9
- Issue
- 6
- Pages
- 400-414
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- PMC
- PMC2722839
- OpenAlex
- W2162262059
- Cited by
- 2,712
- References
- 236
- Citations by year
- 2026: 99 · 2025: 156 · 2024: 161 · 2023: 206 · 2022: 182 · 2021: 205 · 2020: 204 · 2019: 180 · 2018: 191 · 2017: 196 · 2016: 148 · 2015: 160 · 2014: 142 · 2013: 151 · 2012: 122
- FWCI
- 9.54
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (R01CA089406, R01 CA 89406, T32CA009109)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- p21, cyclin-dependent kinase inhibitors, cell cycle arrest, therapeutic target, cell transformation
- MeSH terms
- Animals, Cell Cycle, Humans, Neoplasms, Tumor Suppressor Protein p53, Cyclin-Dependent Kinase Inhibitor p21
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
